Showing 1 - 10 of 270
This paper examines trends in computer usage and the effect on productivity growth for a sample of federal government agencies over the period from 1987 to 1992. We link data from the Bureau of Labor Statistics (BLS) on the growth in real output per employee with data from a marketing research...
Persistent link: https://www.econbiz.de/10013229119
Persistent link: https://www.econbiz.de/10001674274
Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at death), hospital utilization, and medical expenditure in Greece during the period 1995 - 2010. The estimates indicate that pharmaceutical innovation increased mean age at death...
Persistent link: https://www.econbiz.de/10010473542
Dean Baker and Adriane Fugh-Berman have published a critique of a study I performed in 2007, entitled "Why has longevity increased more in some states than in others?ʺ One of the conclusions I drew from that study was that medical innovation accounts for a substantial portion of recent...
Persistent link: https://www.econbiz.de/10003861794
There are two types of prescription drug cost offsets. The first type of cost offset - from prescription drug use - is primarily about the effect of changes in drug quantity (e.g. due to changes in out-of-pocket drug costs) on other medical costs. The second type of cost offset - the cost offset...
Persistent link: https://www.econbiz.de/10011987056
I investigate the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. First, I examine the effect of the vintage of prescription drugs (and other variables) on the life expectancy and age-adjusted mortality rates of residents of Germany, using...
Persistent link: https://www.econbiz.de/10003977959
Persistent link: https://www.econbiz.de/10001765273
Persistent link: https://www.econbiz.de/10001695895
Persistent link: https://www.econbiz.de/10001646748
Persistent link: https://www.econbiz.de/10001966562